Source | Pathogen | Cytokine/protein expression | Infectivity | References |
---|---|---|---|---|
Human primary small airway | Influenza A | Aqp5−, CK-14+, SP-C−, IL-1β++, IL-6++, IL-8++, IL-10+, MCP-1− | Not measured | |
Human primary ATI and ATII | Influenza A | IFN-β+, IL-6+, RANTES+, MCP-1+, IP-10+ | ATI—H5N1 and H1N1: ~ 105 TCID50/mL (48 h peak) ATII—H5N1 and H1N1: ~ 106 TCID50/mL (72 h peak) | [22] |
NHBE | HRV-C HBoV | TNF-α+, IP-10+, IL-6+, IL-8+ | Not measured | [24] |
Calu-3 | RSV HRV 14, 16 | RANTES+ Without PBMC: FGF-Basic+, IL-15+*, IP-10+, IL-6+, ENA-78+, MIP-1β− With PBMC: FGF-Basic+, IL-15+*, IP-10+, IL-6+, MIP-1β+*, IFN-α+*, MCP-2+, IL-28A+*, ENA-78+ | 106 RSV-A genome copies/mL (Peak on day 15) HRV 16: 0.04 1/Ct (peak on day 4) HRV 14: 0.07 1/Ct (peak on day 5) | [25] |
16HBE14o− | ANDV | IP10+, IL-6+, IL-8+, RANTES− | 50,000 FFU/mL (peak on day 15) | [26] |
HCC38 | MV | Not measured | 100% GFP + epithelial cells four days p.i | [64] |
A549 | LPS IAV | IL-6+, IL-8+ IL-29++ | Not measured  ~ 1 × 107pfu/mL IAV titer at 24 h p.i | [28] [27] |